The secondary MR risk stratification largely depends on the underlying cardiac disease and is based on clinical and physical examination, laboratory tests (i.e., BNP or NTproBNP in heart failure), ECG, echocardiography, maximal exercise stress test/CPET, cardiac magnetic resonance, and 24-h ECG monitoring. This evidence concerns the gene NPPB and heart failure.